Bluejay Diagnostics Inc (BJDX)vsEli Lilly and Company (LLY)
BJDX
Bluejay Diagnostics Inc
$0.88
-12.14%
HEALTHCARE · Cap: $1.19M
LLY
Eli Lilly and Company
$1,155.27
-4.55%
HEALTHCARE · Cap: $1.02T
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
BJDX
Avoid26
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BJDX
The strongest argument for BJDX centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : BJDX
The primary concerns for BJDX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Key Dynamics to Monitor
BJDX profiles as a value stock while LLY is a growth play — different risk/reward profiles.
BJDX carries more volatility with a beta of 0.88 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 26/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bluejay Diagnostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bluejay Diagnostics Inc. is an innovative medical technology company focused on revolutionizing patient care through its cutting-edge diagnostic solutions, with a strong emphasis on early disease detection. Utilizing a proprietary platform that combines advanced artificial intelligence with point-of-care testing, Bluejay enhances diagnostic accuracy and accelerates result delivery, thereby equipping healthcare providers with critical insights in real-time. The company is strategically poised to confront notable healthcare challenges and fulfill the growing demand for reliable and advanced diagnostic tools, leveraging its robust commitment to research and development in a rapidly evolving medical landscape.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?